适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Abivax
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.Moderately to severely active ulcerative colitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-509226-21-00Abivax24
招募中
1 期
A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.Healthy female participants of childbearing potential.MedDRA version: 21.1Level: LLTClassification code: 10003268Term: Arthritis rheumatoid Class: 10028395MedDRA version: 20.1Level: PTClassification code: 10021972Term: Inflammatory bowel disease Class: 100000004856CTIS2023-505297-15-00Abivax36
进行中（未招募）
1 期
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouthCTIS2023-508030-33-00Sanofi-Aventis Recherche & Developpement13
进行中（未招募）
1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864Advanced MelanomaCTIS2023-507377-17-00Microbiotica Limited40
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200